Strong Q2 For Cipla Amid Waning Generic Nexium Impact
This article was originally published in PharmAsia News
Cipla has reported robust growth in the second quarter, buoyed by one-off revenues from the US, but the Indian company sought to temper full-year top-line expectations in view of the strong first-half showing.
You may also be interested in...
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.